散发性高级别浆液性卵巢癌中BRCA基因突变的临床意义与分布
研究纳入2015年1月至2016年1月郑州大学附属肿瘤医院68例散发性高级别浆液性卵巢癌患者,用二代测序检测BRCA基因,化学发光法检测血清肿瘤标志物。BRCA突变率22%(15/68),BRCA突变型患者血清CA125水平明显高于野生型(t=-3.536,P=0.003),且多因素分析显示CA125高水平是BRCA突变的独立危险因素(P=0.007)。
要点
- 68例散发性HGSOC中BRCA突变率22%(15/68),BRCA1为16%(11/68)、BRCA2为6%(4/68)。
- BRCA突变型患者血清CA125水平明显高于野生型(t=-3.536,P=0.003)。
- CA125高水平是散发性HGSOC患者BRCA突变的独立危险因素(P=0.007)。
核心结论
- 血清CA125高水平能够提示散发性HGSOC患者BRCA基因突变情况。
- BRCA基因突变型患者对以铂类药物为基础的联合化疗方案更加敏感,能够指导临床化疗用药。
研究设计与样本
- 收集2015年1月至2016年1月郑州大学附属肿瘤医院收治的病理诊断为HGSOC、家族中无乳腺癌或卵巢上皮性癌病史且本人无乳腺癌病史的散发性HGSOC患者共68例。
- 所有患者入院前未予任何治疗,采用二代测序技术检测BRCA基因,化学发光法检测血清CEA、CA125、CA199、HE4水平。
- 单因素分析采用χ²检验、Fisher确切概率法,多因素分析采用logistic回归法。
主要发现
- 68例中15例存在BRCA基因突变,突变率22%(15/68),其中BRCA1突变率16%(11/68)、BRCA2突变率6%(4/68),4例为新发突变。
- BRCA突变型患者血清CEA、CA199、HE4水平均低于BRCA野生型患者,但差异均无统计学意义(P>0.05)。
- BRCA突变型患者血清CA125水平明显高于BRCA野生型患者(t=-3.536,P=0.003)。
- Pearson线性相关分析显示CEA与CA199呈明显正相关(r=0.897,P<0.01),CA125与HE4呈明显正相关(r=0.494,P<0.01)。
- 单因素分析显示BRCA突变与年龄、手术病理分期、远处转移及血清CEA、CA199、HE4水平均无关(P>0.05),而与血清CA125水平、铂类药物敏感性均明显相关(P<0.05);多因素分析显示血清CA125高水平是BRCA突变的独立危险因素(P=0.007)。
临床怎么用
- 作者认为血清CA125高水平能够提示散发性HGSOC患者BRCA基因突变情况。
- 作者认为BRCA基因突变型患者对以铂类药物为基础的联合化疗方案更加敏感,能够指导临床化疗用药。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To investigate the mutations of BRCA genes in sporadic high grade serous ovarian cancer (HGSOC) and study its clinical significance. Methods: Sixty-eight patients between January 2015 and January 2016 from the Affiliated Cancer Hospital of Zhengzhou University were collected who were based on pathological diagnosis of ovarian cancer and had no reported family history, and all patients firstly hospitalized were untreated in other hospitals before. (1) The BRCA genes were detected by next-generation sequencing (NGS) method. (2) The serum tumor markers included carcinoembryonic antigen (CEA), CA(125), CA(199), and human epididymis protein 4 (HE4) were detected by the chemiluminescence methods, and their correlation was analyzed by Pearson linear correlation. Descriptive statistics and comparisons were performed using two-tailed t-tests, Pearson's chi square test, Fisher's exact tests or logistic regression analysis as appropriate to research the clinicopathologic features associated with BRCA mutations, including age, International Federation of Gynecology and Obstetrics (FIGO) stage, platinum-based chemotherapy sensitivity, distant metastases, serum tumor markers (STM) . Results: (1) Fifteen cases (22%, 15/68) BRCA mutations were identified (BRCA1: 11 cases; BRCA2: 4 cases), and four novel mutations were observed. (2) The levels of CEA, CA(199), and HE4 were lower in BRCA mutations compared to that in control group, while no significant differences were found (P>0.05), but the level of CA(125) was much higher in BRCA mutation group than that in controls (t=-3.536, P=0.003). Further linear regression analysis found that there was a significant linear correlation between CA(125) and HE4 group (r=0.494, P<0.01), and the same correlation as CEA and CA(199) group (r=0.897, P<0.01). (3) Single factor analysis showed that no significant differences were observed in onset age, FIGO stage, distant metastasis, and STM between BRCA(+) and BRCA(-) group (P>0.05), while significant differences were found in CA(125) and sensitivity to platinum-based chemotherapy between the patients with BRCA mutation and wild type (P<0.05). The multiple factors analysis showed that the high level of CA(125) was a independent risk factor of BRCA mutations in sporadic HGSOC (P=0.007). Conclusion: The combination of CA(125) with BRCA have great clinical significance, the mutation of BRCA gene could guild the clinical chemotherapy regiments. 目的:探讨散发性高级别卵巢浆液性癌(HGSOC)的BRCA基因突变情况及其临床意义。 方法:收集2015年1月-2016年1月郑州大学附属肿瘤医院收治的病理诊断为HGSOC且患者家族中无乳腺癌或卵巢上皮性癌病史、患者本人无乳腺癌病史者(即散发性HGSOC患者)共68例纳入本研究,所有患者入院前未予任何治疗。(1)采用第2代基因测序(NGS)技术检测散发性HGSOC患者的BRCA基因突变情况;(2)采用化学发光法检测散发性HGSOC患者血清肿瘤标志物包括癌胚抗原(CEA)、CA(125)、CA(199)、人附睾蛋白4(HE4)的表达水平,并采用Pearson线性相关分析法对散发性HGSOC患者不同血清肿瘤标志物的水平进行相关性分析;(3)对影响散发性HGSOC患者BRCA基因突变的因素(包括年龄、手术病理分期、远处转移、铂类药物敏感性以及血清CEA、CA(125)、CA(199)、HE4水平等)进行分析,单因素分析采用χ(2)检验、Fisher确切概率法,多因素分析采用logistic回归法。 结果: (1)68例散发性HGSOC患者中,15例患者存在BRCA基因突变,BRCA基因突变率为22%(15/68),其中BRCA1基因突变率为16%(11/68)、BRCA2基因突变率为6%(4/68);且15例BRCA基因突变患者中4例为新发突变。(2)BRCA基因突变型患者的血清CEA、CA(199)、HE4水平均低于BRCA基因野生型(即BRCA基因未突变)患者,但两者分别比较,差异均无统计学意义(P>0.05);而BRCA基因突变型患者的血清CA(125)水平明显高于BRCA基因野生型患者(t=-3.536,P=0.003)。进一步行Pearson线性相关分析显示,CEA与CA(199)(r=0.897,P<0.01)、CA(125)与HE4(r=0.494,P<0.01)之间均呈明显正相关。(3)单因素分析显示,BRCA基因突变与散发性患者的年龄、手术病理分期、远处转移以及血清CEA、CA(199)、HE4水平均无关(P>0.05),而与血清CA(125)水平、铂类药物敏感性均明显相关(P<0.05);多因素分析显示,血清CA(125)高水平是影响散发性HGSOC患者BRCA基因突变的独立危险因素(P=0.007)。 结论:血清CA(125)高水平能够提示散发性HGSOC患者BRCA基因突变情况;BRCA基因突变型患者对以铂类药物为基础的联合化疗方案更加敏感,能够指导临床化疗用药。.
引用
- Liu WL, Wang ZZ, Zhao JZ, et al. [Clinical significance and distribution of BRCA genes mutation in sporadic high grade serous ovarian cancer]. Zhonghua Fu Chan Ke Za Zhi. 2017. PMID: 28190312. doi:10.3760/cma.j.issn.0529-567X.2017.01.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。